Top Markets
Coin of the day
Synairgen plc Synairgen plc

Synairgen plc

SNG
Clasificación en acciones #40400
Synairgen plc specializes in the research and development of pharmaceutical... Synairgen plc specializes in the research and development of pharmaceutical treatments for various respiratory conditions. Its product pipeline includes SNG001, an inhaled interferon beta currently being developed for COVID-19. The company is also advancing an inhaled form of interferon beta (IFN-ß) through Phase II clinical trials for the management of asthma triggered by common colds and influenza, as well as for the treatment or prevention of chronic obstructive pulmonary disease. Furthermore, Synairgen is developing a LOXL2 inhibitor intended for treating idiopathic pulmonary fibrosis (IPF). To support the development of this LOXL2 inhibitor, the company maintains a licensing and collaboration agreement with Pharmaxis Ltd. Synairgen plc was established in 2004 and is headquartered in Southampton, United Kingdom.
Precio por acción
$0.01292666
Última sincronización: 2025-04-08
Capitalización bursátil
$157.54K
Cambio (1 día)
6.84%
Cambio (1 año)
0.00%
País
GB
Comercio Synairgen plc (SNG)

Categoría

Historial del precio de la acción de Synairgen plc (SNG)
Precio más alto de cierre: $0.01 el 2025-04-01

Precio más bajo de cierre: $2.04 el 2004-10-01
Historial del precio de la acción de Synairgen plc desde 2004 hasta 2026
Desempeño anual del precio de la acción
Año Rendimiento
2025 -66.26%
2024 -44.21%
2023 -52.93%
2022 -92.61%
2021 77.16%
2020 1,567.16%
2019 -48.13%
2018 14.84%
2017 -14.89%
2016 -49.84%
2015 -35.02%
2014 -37.63%
2013 15.10%
2012 50.92%
2011 14.84%
2010 -28.85%
2009 88.33%
2008 -77.12%
2007 -24.86%
2006 -99.32%
2005 209.00%
2004 0.00%
Precio de la acción de empresas similares o competidoras
Empresa Precio de la acción Cambio 1a% País
$517.18 30.63%
US
$857.76 32.66%
NL
$744.96 8.94%
CH
$1.08K -6.68%
KR
$259.89 16.65%
BE